Skip to content

CoCo in COPD treatment: Evaluation of use, satisfaction and clinical effects.

CoCo in COPD treatment: Evaluation of use, satisfaction and clinical effects.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21635
Enrollment
30
Registered
2011-09-19
Start date
2011-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Telemedicine Self-management Physical Activity

Interventions

The primary objective of this study is to evaluate the CoCo application in the regular treatment of the MST and associated physiotherapy practices. We will investigate the use of the application, the
2. Online webportal with online training program
3. Self-management of exacerbations by a triage diary on a smartphone. In addition, CoCo has a telemonitoring module for the patient and the professional, for monitoring the progress of the patient,

Sponsors

Roessingh Research and Development
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. A clinical diagnosis of COPD according to the GOLD criteria; 2. No exacerbation in the month prior to enrolment; 3. > or = 3 exacerbations or one hospitalization for respiratory problmens in the two years preceeding study entry; 4. (Ex)smoker; 5. Age > 40 years; 6. Post-bronchodilator FEV1 25-80% of predicted; 7. Able to understand and read Dutch; 8. Internet access at home.

Exclusion criteria

Exclusion criteria: 1. Serious other disease with a low survival rate; 2. Other diseases influencing bronchial symptoms and/or lung function (e.g. cardiac insuficiency, sarcoidosis); 3. Severe psychiatric illness; 4. Uncontrolled diabetes mellitus during a COPD exacerbation in the past or a hospitalization for diabetes mellitus in the two year preceding the study; 5. Need for regular oxygen therapy (>16 h per day or pO2<7.2 kPa); 6. Maintenance therapy with antibiotics; 7. Known alpha1-antitrypsine deficiency; 8. Disorders or progressive disease seriously influencing daily activities (e.g. amputation, paralysis, progressive muscle disease); 9. Impaired hand function causing inability to use application.

Design outcomes

Primary

MeasureTime frame
The CoCo application will be evaluated among patients in terms of use of the application (registered by system), satisfaction with the application, satisfaction with received care, and quality of care.

Secondary

MeasureTime frame
Outcome measures to evaluate the clinical effects are: Exacerbations (number, duration), amount of activity, exercise tolerance, fatigue, health status and symptoms, and quality of life.

Contacts

Public ContactM. Tabak

Roessinghsbleekweg 33b

m.tabak@rrd.nl+31 (0)53 4875777

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)